Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

October 30, 2024

Study Completion Date

December 30, 2024

Conditions
Hepatic Carcinoma
Interventions
DRUG

Sintilimab

Sintilimab (200mg) was administered intravenously over 30-60 min every 3 weeks.

PROCEDURE

Microwave Ablation

The ablation area should covered at least two thirds the size of the nodules.

PROCEDURE

TACE

Patient was treated with epirubicin lipiodol emulsion(Epirubicin 40mg, Lipiodol 10ml).Embolic materials such as gelfoam or microsphere was aslo administered until complete stasis in segmental or subsegmental arterial branches.

Trial Locations (1)

200032

Department of Interventional Radiology, Zhongshan Hospital, Fudan University., Shanghai

All Listed Sponsors
collaborator

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

lead

Shanghai Zhongshan Hospital

OTHER